Venapuncture

PROCEDURE8 trials

Sponsors

University Hospital, Ghent

Conditions

PsoriasisPsoriasis Vulgaris

Phase 4

Dose Tapering Study of Adalimumab in Psoriasis

TerminatedNCT04028713

University Hospital, GhentPsoriasis Vulgaris

Start: 2021-02-16End: 2022-03-22Updated: 2024-09-19

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

CompletedNCT04080661

University Hospital, GhentPsoriasis Vulgaris

Start: 2018-03-22End: 2023-12-31Updated: 2024-09-19

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

CompletedNCT04080648

University Hospital, GhentPsoriasis Vulgaris

Start: 2018-06-27End: 2023-12-31Updated: 2024-09-19

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients

CompletedNCT04083612

University Hospital, GhentPsoriasis Vulgaris

Start: 2020-05-04End: 2023-12-31Updated: 2024-09-19

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients

RecruitingNCT05683015

University Hospital, GhentPsoriasis Vulgaris

Start: 2022-08-22End: 2025-12-31Target: 100Updated: 2024-01-18

A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated

CompletedNCT05683054

University Hospital, GhentPsoriasis

Start: 2020-08-11End: 2022-08-22Updated: 2023-01-12

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

RecruitingNCT05685940

University Hospital, GhentPsoriasis Vulgaris

Start: 2020-04-05End: 2024-12-31Target: 100Updated: 2024-02-05

Unknown Phase

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

RecruitingNCT04080635

University Hospital, GhentPsoriasis Vulgaris

Start: 2018-12-14End: 2024-12-31Target: 100Updated: 2024-09-19

Related Papers

Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice

Journal of Clinical Medicine2022-05-2612 citations